Monthly digital financial hardship screening for people with advanced cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with advanced or metastatic cancer receiving outpatient systemic therapy with non-curative intent will be enrolled and receive either monthly remote digital financial hardship screening with connections to financial navigation resources or enhanced usual care. The digital screening is delivered monthly to identify financial distress and trigger referrals to financial navigation and support. Primary patient-centered outcomes include financial worry, health-related quality of life, symptom burden, and patient-reported treatment adherence, with exploratory outcomes including overall survival, patient-reported economic burden, support received, coping strategies, and insurance literacy. The intervention builds on preliminary data suggesting screening can improve links to assistance and seeks to determine whether repeated remote screening leads to better patient-centered outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Minimum age of 21
2. Understands English and/or Spanish
3. Has a diagnosis of advanced/metastatic cancer
4. Currently undergoing systemic therapy (enteral or parenteral) with non-curative intent
5. Has been receiving treatment for at least 2 months
6. Life expectancy of at least 6 months, in the opinion of the treating oncologist
7. Cognitively able to give informed consent

Exclusion Criteria:

1. Under the age of 21
2. Does not understand English or Spanish
3. Has cognitive deficits that would preclude understanding of consent form and/or questionnaires
4. Undergoing treatment with curative intent (e.g., adjuvant chemotherapy for breast, lung, or ovarian cancer, primary curative therapy for testis cancer or lymphoma)
5. Not undergoing systemic therapy (enteral or parenteral) with non-curative intent
6. Receiving treatment for fewer than 2 months
7. Life expectancy is less than 6 months, in the opinion of the treating oncologist

Where it's running

• Dignity Health
  Phoenix, Arizona, United States Recruiting
• New Hampshire Oncology-Hematology, PA
  Concord, New Hampshire, United States Recruiting
• Solinsky Center for Cancer Care
  Manchester, New Hampshire, United States Recruiting
• New York City Health and Hospitals
  New York, New York, United States Recruiting
• Sanford Health
  Fargo, North Dakota, United States Recruiting
• Gibbs Cancer Center
  Spartanburg, South Carolina, United States Recruiting

Study contacts

• Principal investigator: Victoria Blinder, MD, MSc — Memorial Sloan Kettering Cancer Center
• Study coordinator: AFT Quality Management Group Inbox
• Email: clinicaltrials.queries@alliancefoundationtrials.org
• Phone: 617-732-8727

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• Treatment of metastatic solid tumors with SLV-154

  This study is testing a new treatment called SLV-154 for people with advanced solid tumors, like certain types of lung and breast cancer, to see how safe it is and how well it works.

  Recruiting at 12 sites Phase 1 Solve Therapeutics · Newport Beach, California and 11 other locations · NCT06771219

• Combining two immunotherapy drugs for MSI-H/dMMR advanced stomach and gastroesophageal junction cancer

  This trial will try two immunotherapy drugs (balstilimab and botensilimab) as first treatment for adults with MSI‑H/dMMR, HER2‑negative advanced or metastatic stomach or gastroesophageal‑junction cancer whose tumors have PD‑L1 CPS ≥5, and will compare that to standard chemotherapy with nivolumab.

  Recruiting at 7 sites Phase 3 Centre Leon Berard · Brest and 6 other locations · NCT06346197

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

• CD70-targeted CAR-T treatment for advanced gynecologic cancer

  This study is testing a new CAR-T treatment that targets CD70 to see if it can help people with advanced gynecologic cancers feel better and improve their outcomes.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhu, Anhui · NCT06215950

• Testing PTX-912 in patients with advanced solid tumors

  This study is testing a new drug called PTX-912 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 3 sites Phase 1 Proviva Therapeutics, Inc. · Duarte, California and 2 other locations · NCT06190886

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.